Merck-AstraZeneca breast cancer drug Lynparza improves long-term survival, clinical trial shows
Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in ...